#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hypersomnia Breast cancer metastatic Hyperinsulinaemic hypoglycaemia Sjogren's syndrome Progressive familial intrahepatic cholestasis Squamous cell carcinoma of the vulva Glycogen storage disease type I Cytokine release syndrome Primary hyperoxaluria Mucopolysaccharidosis III Squamous cell carcinoma of head and neck Fatty acid oxidation disorder Cytomegalovirus infection Lupus nephritis Metachromatic leukodystrophy More trials…

    Learn about Rare Diseases

    Bronchopulmonary dysplasia – Treatment Ehlers-Danlos syndrome – Treatment Pleomorphic leiomyosarcoma Primary immunodeficiency syndrome – Life with Disease Angiosarcoma recurrent – Trials in Disease Mast cell activation syndrome Metachromatic leukodystrophy – Treatment Optic glioma – Trials in Disease Myelodysplastic syndrome with excess blasts – Basic Information Congenital hypotransferrinaemia – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Palonosetron Triheptanoin Aavanc80-5'Hotof Ganciclovir Sodium ARI0008 Befiradol (18F) Anhydrous Glucose Bp [18F]Mc225 Regn5668 E2814 Deferoxamine Mesilate Fexofenadine Teplizumab Cetuximab Gsk4011499 Tulisokibart Mexiletine Adrc AGANIRSEN Etoricoxib More therapies…

    Learn about Your Condition

    Patent ductus arteriosus Pelvic venous thrombosis Meningioma malignant Proteinuria Thrombolysis Haemorrhage Normal pressure hydrocephalus Primary hyperthyroidism Embolism Obesity Infantile spasms Primary adrenal insufficiency Chronic spontaneous urticaria Bone metabolism disorder Uveitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

    Recruiting

    2 1
    Investigated Drugs:
    • XMAB942
    Bulgaria Croatia France Germany Greece Hungary +5

  • Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

    Recruiting

    3 1 1
    Investigated Diseases:
    • Haemophilia A without inhibitors
    • Haemophilia B without inhibitors
    • Factor IX deficiency
    Investigated Drugs:
    • Concizumab
    Bulgaria France Greece Italy Lithuania Norway +4

  • A study to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight and type 2 diabetes

    Recruiting

    3 1
    Investigated Drugs:
    • LY3841136 SODIUM
    Czechia Germany Poland Slovakia Spain

  • Safety and dose‑finding study of trazodone hydrochloride and psilocybin in patients with treatment‑resistant depression

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • TRAZODONE HYDROCHLORIDE
    • Dry Extract From Psilocybe Cubensis (15-25:1), Extraction Solvent: Methanol
    Italy

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Mirikizumab
    • Tirzepatide
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Efficacy and Safety of Brenipatide (LY3537031) in Adults with Irritable Bowel Syndrome‑Constipation (IBS‑C) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

    Recruiting

    2 1
    Investigated Diseases:
    • Irritable bowel syndrome
    Investigated Drugs:
    • LY3537031
    Belgium Spain
1 2 3 … 1,657
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!